A year after Roche's Alzheimer's failure, scientists reflect on what could have been

A year after Roche's Alzheimer's failure, scientists reflect on what could have been

Source: 
Fierce Biotech
snippet: 

Almost a year to the day after Genentech revealed that its Alzheimer’s disease drug gantenerumab failed a phase 3 trial, the data are appearing in The New England Journal of Medicine, giving scientists a chance to reflect on what was learned.